takeovers by Valeant Pharmaceuticals ( VRX +2.5% ) and Mylan ( MYL +2.2% ). VRX routinely looks at potential acquisitions ..... the picture. And it would be virtually impossible for MYL , with a market value of $11.7B, to buy the combined
Actavis ( ACT ), which has rebuffed overtures from both Valeant ( VRX ) and more recently Mylan ( MYL ), may soon receive a bid from Novartis ( NVS ), WSJ says. "Intense price competition and fewer opportunities to cash in on
By ITT Investment Research: Mylan , Inc. ( MYL ) is the fourth largest generics ..... superior earnings growth prospects Mylan 's shares trade at a P/E 2013 ..... maintained Solid Q1 2013 results Mylan reported Q1 2013 total revenues
Mylan ( MYL +0.4% ) receives final approval from the FDA for its Abbreviated New ..... S. sales of approximately $152.8M for the 12 months ending March 31. MYL has already begun shipping. Post your comment!
NEW YORK (Reuters) - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
NEW YORK, May 14 (Reuters) - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the...
Actavis ( ACT +1.2% ) spikes on reports that the company recently turned away a $15B bid from Mylan ( MYL +0.1% ). Post your comment!
Although Mylan MYL reported encouraging European and branded ..... negative currency effects in Asia slowed Mylan ’s growth trajectory. Following the large ..... some slowdown in growth this year, but Mylan ’s first-quarter results fell slightly
Mylan ( MYL ) Q1 2013 Earnings Call May 02, 2013 4:30 pm ET Executives Kris King ..... br/><a href='http://seekingalpha.com/article/1397171- mylan -management-discusses-q1-2013-results-earnings-call-transcript
* First-quarter adjusted EPS $0.62 vs Street estimate $0.61